Information Provided By: 
Fly News Breaks for November 18, 2019
NVO
Nov 18, 2019 | 04:54 EDT
Barclays analyst Emmanuel Papadakis upgraded Novo Nordisk to Overweight from Equal Weight with a price target of 445 kroner.
News For NVO From the Last 2 Days
NVO
Apr 24, 2024 | 15:59 EDT
Senator Bernie Sanders is set to lead a Senate investigation into the high prices charged by Novo Nordisk for its diabetes and anti-obesity medications Ozempic and Wegovy, The Financial Times' Oliver Barnes reports. Sanders wrote to Novo Nordisk CEO Lars Fruergaard Jorgensen to inform him the U.S. committee that oversees healthcare is probing "the outrageously high prices" the company charges for the drugs, saying that the drugs "will not do any good for the millions of patients who cannot afford them." Reference Link
